Safety profile of anti-gout agents: An update

Current Opinion in Rheumatology

Volumn 26, Issue 2, 2014, Pages 162-168

  Stamp, Lisa K ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

allopurinol; colchicines; febuxostat; urate lowering therapy

Indexed keywords

ALLOPURINOL; COLCHICINE; DRUG INTERACTIONS; GOUT; GOUT SUPPRESSANTS; HLA-B ANTIGENS; HUMANS; INTERLEUKIN-1; POLYETHYLENE GLYCOLS; RISK FACTORS; SAFETY; THIAZOLES; URATE OXIDASE;

EID: 84894063769     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000031     Document Type: Review

References (56)

1. Khanna D, Khanna P, Fitzgerald J, et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012; 4:1447-1461
2. Martinon F, Petrilli V, Mayor A, et al. Gout-Associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241
3. Cronstein B, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96:994-1002
4. Terkeltaub R, Furst D, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare. Arthritis Rheum 2010; 62:1060-1068
5. Kuncl R, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316:1562-1568
6. Cook M, Ramos E, Peterson J, et al. Colchicine neuromyopathy in a renal transplant patient with normal muscle enzyme levels. Clin Nephrol 1994; 42:67-68
7. Rieger E, Halasz N, Wahlstrom H. Colchicine neuromyopathy after renal transplantation. Transplantation 1990; 49:1196-1198
8. Tapal M. Colchicine myopathy. Scand J Rheumatol 1996; 25:105-106
9. Rana S, GiulianiM, Oddis C, et al. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: Case studies of three patients. Clin Neurol Neurosurg 1997; 99:266-270
10. Wluka A, Ryan P, Miller A, et al. Postcardiac transplantation gout: Incidence and therapeutic complications. J Heart Lung Transplant 2000; 19:951-956
11. Mikuls T, MacLean C, Oliveri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004; 50:937-943
12. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 2012; 39:1458-1464
13. Nidorf S, Eikelboom J, Budgeon C, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61:404-410
14. Federal Drug Administration. New safety information for colchicine. 2009; http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm 174315.htm
15. Terkeltaub R, Furst D, DiGiacinto J, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011; 63:2226-2237
16. Colcrys. Colchicine dosing recommendations. http://wwwcolcryscom/assets/ pdf/COLCRYS-Full-Prescribing-Informationpdf. 2009
17. Pope R, Tschopp J. The role of interleukin-1 and the inflammasome in gout: Implications for therapy. Arthritis Rheum 2007; 56:3183-3188
18. Schlesinger N, Alten R, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double blind trials and their initial extensions. Ann Rhem Dis 2012; 71:1839-1848
19. Mitha E, Schumacher H, Fouche L, et al. Rilonacept for acute gout flare during initiation of uric acid lowering therapy: Results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology 2013; 52:1285-1292
20. Ryu H, Song R, Kim H, et al. Clinical Risk Factors for adverse events in allopurinol users. J Clin Pharmacol 2012; 53:211-216
21. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: Walking the tightrope between adequate urate lowering and adverse events. Sem Dial 2007; 20:391-395
22. Hande K, Noone R, Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56
23. Hung S, Chung W, Liou L, et al. HLA-B-5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 2005; 102:4134-4139
24. Lupton G, Odom R. Severe allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979; 72:1361-1368
25. Singer J, Wallace S. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29:82-87
26. Lang P. Severe hypersensitivity reactions to allopurinol. South Med J 1979; 72:1361-1368
27. Young J, Boswell R, Nies A. Severe allopurinol hypersensitivity. Arch Int Med 1974; 134:553-558
28. Arellano F, Sacristan J. Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother 1993; 27:337-343
29. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-1622
30. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B-5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19:704-709
31. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high risk drugs. Pharmacogenet Genomics 2008; 18:99-107
32. Stamp L, Taylor W, Jones P, et al. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64:2529-2536
33. Perez-Ruiz F, Hernando I, Villar I, et al. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: Another insight into allopurinol related toxicity. J Clin Rheumatol 2005; 11:129-133
34. Vazquez-Mellado J, Meono Morales E, Pacheco-Tena C, et al. Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60:981-983
35. Dalbeth N, Kumar S, Stamp LK, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout. J Rheumatol 2006; 33:1646-1650
36. Cao Z-H, Wei Z-Y, Shang J-Y, et al. HLA-B-58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 2012; 13:1193-1201
37. Chiu M, Hu M, Ng M, et al. Association between HLA-B-58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 2012; 167:44-49
38. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93:153-158
39. Lee M, Chen Y, Shen C. A prospective study of HLA-B-5801 genotyping for the prevention of allopurinol induced severe cutaneous adverse reactions. Clin Pharm Ther 2012; 91 (Suppl 1); S107
40. Yeo S. HLA-B-5801: Utility and cost effectiveness in the Asia-Pacific region. Int J Rheum Dis 2013; 16:254-257
41. Lee M, Stocker S, Anderson J, et al. Initiating allopurinol therapy: Do we need to know the patient's human leucocyte antigen status? Int Med J 2012; 42:411-416
42. Maekawa K, Nishikawa J, Kaniwa N, et al. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLAB-58:01: A partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese. Drug Metab Pharmacokinet 2012; 27:447-450
43. Stamp L, O'Donnell J, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Arthritis Rheum 2011; 63:412-421
44. Reinders M, Haagsma C, Jansen T, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009; 68:892-897
45. Paisanainsup T, Breitenstein M, Schousboe J. Association between adverse reactions to allopurinol and exposures to high maintenance doses: Implications for management of patients using allopurinol. J Clin Rheumatol 2013; 19:180-186
46. Khanna D, Fitzgerald J, Khanna P, et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res 2012; 64:1431-1446
47. Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients-65 years of age. BMC Geriatr 2012; 12:11
48. Becker M, MacDonald PA, Hunt B, et al. Diabetes and gout: Efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab 2013; 15:1049-1055
49. Gandhi P, Gentry W, Bottorff M. Cardiovascular thromboembolic events associated with febuxostat: Investigation of cases from the FDA adverse event reporting system database. Semin Arthritis Rheum 2013; 42:562-566
50. White WB, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J 2012; 164:14-20
51. Chohan S, Becker M. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011; 38:1957-1959
52. Abeles AM. Febuxostat hypersensitivity. J Rheumatol 2012; 39:659
53. Horikoshi R, Akimoto T, Inoue M, et al. Febuxostat for hyperuricaemia: Experience with patients on chronic hemodialysis treatment. Clin Exp Nephrol 2013; 17:149-150
54. Sundy J, Baraf H, Yood R, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. J Am Med Assoc 2011; 306:711-720
55. Becker M, Baraf H, Yood R, et al. Long-Termsafety of pegloticase in chronic gout refractory to conventional treatment. Ann Rhem Dis 2013; 72:1469-1474
56. Kavanaugh A, Ruderman E. Pegloticase and concomitant urate-lowering therapies: ACR hotline. 2012; http://wwwrheumatologyorg/Publications/ Hotline/Pegloticase-And-Concomitant-Urate-lowering-Therapies/.